{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:11:41Z","timestamp":1787508701285,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.vaccine.2014.11.047","type":"journal-article","created":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T16:47:05Z","timestamp":1418057225000},"page":"519-522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Safety of quadrivalent human papillomavirus vaccine (Gardasil\u00ae) in pregnancy: Adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006\u20132013"],"prefix":"10.1016","volume":"33","author":[{"given":"Pedro L.","family":"Moro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenlik","family":"Zheteyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oidda I.","family":"Museru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.11.047_bib0005","unstructured":"Gardasil (human papillomavirus quadrivalent [types 6, 11, 16, 18] vaccine, recombinant): product information and supporting documents. Food and Drug Administration. Available from: http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm094042.htm [accessed 01.10.13]."},{"issue":"RR-2","key":"10.1016\/j.vaccine.2014.11.047_bib0010","first-page":"1","article-title":"Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2014.11.047_bib0015","unstructured":"Merck & Co., Inc. Pregnancy Registry for GARDASIL. Available from: http:\/\/www.merckpregnancyregistries.com\/gardasil.html [accessed 20.03.14]."},{"key":"10.1016\/j.vaccine.2014.11.047_bib0020","series-title":"Meeting of the Advisory Committee on Immunization Practices (ACIP)","article-title":"Merck Pregnancy Registry for qHPV Vaccine (Gardasil\u00ae): exposure during pregnancy June 1, 2006 through May 31, 2012","author":"Lievano","year":"2013"},{"issue":"23","key":"10.1016\/j.vaccine.2014.11.047_bib0025","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00006454-200404000-00002","article-title":"Understanding vaccine safety information from the Vaccine Adverse Event Reporting System","author":"Varricchio","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2014.11.047_bib0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/0264-410X(94)90315-8","article-title":"The Vaccine Adverse Event Reporting System (VAERS)","volume":"12","author":"Chen","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.047_bib0035","series-title":"Medical dictionary for regulatory activities maintenance and support services organization","year":"2010"},{"key":"10.1016\/j.vaccine.2014.11.047_bib0040","first-page":"52252","article-title":"21 Code of Federal Regulation Part 600.80. Postmarketing reporting of adverse experiences","volume":"62","author":"Food and Drug Administration","year":"1997","journal-title":"Federal Regist"},{"key":"10.1016\/j.vaccine.2014.11.047_bib0045","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2010.08.050","article-title":"Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990\u20132009","volume":"204","author":"Moro","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2014.11.047_bib0050","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1016\/j.vaccine.2010.09.021","article-title":"Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009\u2013January 31, 2010","volume":"28","author":"Vellozzi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.11.047_bib0055","series-title":"Williams obstetrics","first-page":"189","article-title":"Prenatal care","year":"2010"},{"issue":"561","key":"10.1016\/j.vaccine.2014.11.047_bib0060","first-page":"e1","article-title":"Reports to the Vaccine Adverse Event Reporting System after hepatitis A and hepatitis AB vaccines in pregnant women","volume":"210","author":"Moro","year":"2014","journal-title":"Am J Obstet Gynecol"},{"issue":"473","key":"10.1016\/j.vaccine.2014.11.047_bib0065","first-page":"e1","article-title":"Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System","volume":"205","author":"Moro","year":"2011","journal-title":"Am J Obstet Gynecol"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2014.11.047_bib0070","article-title":"Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women","volume":"207","author":"Zheteyeva","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2014.11.047_bib0075","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(09)61877-8","article-title":"Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines","volume":"374","author":"Black","year":"2009","journal-title":"Lancet"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2014.11.047_bib0080","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/AOG.0b013e3181c2a122","article-title":"Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6\/11\/16\/18 vaccine","volume":"114","author":"Dana","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2014.11.047_bib0085","doi-asserted-by":"crossref","first-page":"93S","DOI":"10.1097\/01.AOG.0000447430.00051.ba","article-title":"No adverse signals observed after exposure to human papillomavirus type 6\/11\/16\/18 vaccine during pregnancy","volume":"123","author":"Goss","year":"2014","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2014.11.047_bib0090","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e3181c2ca21","article-title":"Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6\/11\/16\/18 vaccine: a combined analysis of five randomized controlled trials","volume":"114","author":"Garland","year":"2009","journal-title":"Obstet Gynecol"},{"issue":"January (4)","key":"10.1016\/j.vaccine.2014.11.047_bib0095","first-page":"69","article-title":"CDC grand rounds: reducing the burden of HPV-Associated cancer and disease","volume":"63","author":"Dunne","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14016041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14016041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T00:24:21Z","timestamp":1538007861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14016041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0264410X14016041"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of quadrivalent human papillomavirus vaccine (Gardasil\u00ae) in pregnancy: Adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006\u20132013","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}